Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trialVsevolod Matveev, Yohann Loriot, Daniel P. Petrylak et al.|The Lancet Oncology|2020Cited by 502
266 Tumour mutation burden (TMB) and efficacy outcomes in the phase III DANUBE study of advanced urothelial carcinoma (UC)Sophie Wildsmith, Jill Walker, Anne L’Hernault et al.|Regular and Young Investigator Award Abstracts|2020Cited by 7